Clinical Trial Update: Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome [Phase 1, Phase 2]

View source ↗

Summary

This update reports completion of a Phase 1/2 study evaluating the glutaminase inhibitor Telaglenastat (CB-839) in combination with azacitidine for advanced mye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia with Multilineage Dysplasia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Telaglenastat (CB-839) (telaglenastat)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-05-14